BUSINESS
Aarti Industries: Is it time to look past inventory headwinds?
FY24 could be another year of consolidation for the industry, unless global growth picks up.
BUSINESS
Fed policy: Is the end in sight for the rate hike cycle?
This could be an appropriate time to start portfolio construction as Fed commentary suggests that some of the financial stability concerns are abating
BUSINESS
Apcotex: Gradual ramp-up of new facilities to drive earnings
Apcotex has a volume-led growth visibility in the near to medium term and margins are expected to pick up later.
BUSINESS
Laurus Labs: Is the worst priced in?
We expect FY24 to be the year of consolidation for top-line growth. Margins are expected to bottom out as operating leverage kicks in first for formulation capacity and later on for CDMO opportunity.
BUSINESS
Syngene: Zoetis opportunity unfolds
Q4 FY23 aided by better-than-expected traction for the 10-year manufacturing deal with Zoetis.
BUSINESS
Is Unichem deal a misstep for Ipca Labs?
The utilisation of the idle assets of Unichem will be key to the success of the deal
BUSINESS
Mankind Pharma IPO: A pricey proposition on branded domestic pharma market
As the company is foraying into newer areas of therapies, particularly chronic, there could be execution hiccups.
BUSINESS
Fermenta Biotech: Time to look beyond near-term cyclical challenges?
Real estate monetization is on works
BUSINESS
Oil Update: What should investors do after the OPEC shocker?
Portfolio construction should be focused on business models that can survive high cost of capital; avoid pockets where the margin of safety is limited
BUSINESS
Sun Pharma: Ransomware attack to eat into operational performance
The situation is evolving and can potentially have a wider reach, possibly involving litigations
BUSINESS
Fed policy: Banking crises may turn out to be a blessing in disguise for inflation goals
Uncertainty and risk to upside in inflation has reduced; the sooner financial stability is achieved is better for investors
BUSINESS
Can the Credit Suisse deal lend enough confidence to Fed in fighting inflation?
High inflation and high interest regime in the longer term would present more complex challenges, not just liquidity
BUSINESS
Ami Organics: Europe plus one trend is taking hold
For the specialty chemicals business, Ami Organics is expanding on the clientele side and investing in process engineering
BUSINESS
NOCIL: What should investors do as company struggles with inventory correction?
NOCIL is aiming to address the shortfall in capacities, after FY24. It is in the process of de-bottlenecking capacities of certain grades, which will help it to meet the demand for one to two years more.
BUSINESS
Is it time to look at this quality chemical play?
There are a few positive developments, both at the macro and micro levels, which investors should take note of
BUSINESS
Apollo Hospitals: A credible profitability road map for pharmacy is the ask
Margin improvement continued in the mature hospitals division, but Apollo 24/7’s operating cost weighed on EBITDA
BUSINESS
Global Health: Faster ramp-up in new facilities adds to financial health
Strong ramp-up in its newer facilities reflect the growing demand for high-end institutional healthcare facilities
BUSINESS
Lupin: Why you need to avoid despite improving US business
The improvement in both top line and margins are expected to be gradual
BUSINESS
KIMS: Ramp-up of newly acquired entities to be key growth driver
KIMS presents a play on the structural demand trend for healthcare facilities
BUSINESS
Aarti Industries: Does it strike the right chemistry for the long term?
Earnings to be driven by capex spending over the medium term
BUSINESS
Navin Fluorine: Keep this quality chemical business on radar during downcycle
Long-term thesis is improving but trading at an expensive multiple
BUSINESS
Zydus Lifesciences: Transdermal opportunity to unfold
The US and domestic formulation businesses help the pharma company to do well in Q3
BUSINESS
Divi’s Labs: Growth trajectory sharply lower, wait for value to emerge
Gross margin contraction and operating deleverage have brought operating margins to levels not seen historically and pose concerns in the mind of investors regarding the near- to medium-term prospects
BUSINESS
SRF: Agrochemical opportunity offsets weakness in other areas
The demand for agrochemicals remains strong as the company remains focused on active ingredients while engaging with global innovators
